Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy.
Almost half of the children with symptomatic dilated cardiomyopathy receive a transplant or die within 2 years; however, cardiac stem cell transplantation has become a promising therapeutic option. The present case demonstrates for the first time, to our knowledge, the intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill 4-month-old child with severe dilated cardiomyopathy. Left ventricular ejection fraction increased from 20% before stem cell transplantation to 41% at 4 months of follow-up.
Lacis
Aris
A
Latvian Centre of Pediatric Cardiology, Children's Hospital, Riga, Latvia.
Erglis
Andrejs
A
D001854:Bone Marrow Cells / Q000166:cytology*; D016026:Bone Marrow Transplantation / Q000379:methods*; D002311:Cardiomyopathy, Dilated / Q000601:surgery*; D016638:Critical Illness; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007267:Injections; D007963:Leukocytes, Mononuclear / Q000637:transplantation*; D009206:Myocardium; D014182:Transplantation, Autologous